Colgate-Palmolive sees 5%–7% non-GAAP EPS growth in 2026
The revised outlook includes a low-single-digit positive foreign-exchange impact on sales and 5% to 7% Base Business EPS growth.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
8-K
Rhea-AI Filing Summary
Colgate-Palmolive (CL) reported third-quarter 2026 net sales of $5,369 million, up 4.6% year over year; organic sales rose 3.6%, including a 0.2% negative impact from lower private-label pet food sales. GAAP diluted EPS increased 3% to $0.94 and non-GAAP Base Business diluted EPS increased 7% to $0.97. GAAP gross profit margin rose 80 basis points to 60.2%. In the first nine months, net sales were $16,055 million, up 6%, GAAP operating profit decreased 5% to $3,069 million and net cash provided by operations was $2,913 million.
Based on current spot rates, full-year 2026 net sales growth is now expected at 4% to 5%, versus 2% to 6% previously, including a low-single-digit positive foreign-exchange impact. Organic sales growth is expected to be broadly in line with nine-month performance, versus 1% to 4% previously. GAAP and Base Business gross profit margin are now expected to be up versus roughly flat previously; Base Business EPS growth is expected at 5% to 7%, versus mid-single-digit previously. The company still expects advertising to increase in dollars and as a percentage of sales and double-digit GAAP EPS growth.
1 point · 0 major0 major · 1 point
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Positive
- Moderate pointBase Business diluted EPS rose 7% to $0.97 in Q3 2026.
Negative
- Moderate pointGAAP operating profit fell 5% in the first nine months of 2026.
Filing Explained
At September 30, 2026, debt less cash and marketable securities was $6,104 million; cash and equivalents were $1,527 million.
For the first nine months of 2026, Colgate-Palmolive reports
8-K Event Classification
2 items: 2.02, 9.01
2 items
Item 2.02
Results of Operations and Financial Condition
Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
Third-quarter net sales: $5,369 million; up 4.6% year over year
GAAP diluted EPS: $0.94 per share; up 3% year over year
Base Business diluted EPS: $0.97 per share; up 7% year over year
+5 more
8 metrics
Third-quarter net sales
$5,369 million; up 4.6% year over year
Third quarter 2026
GAAP diluted EPS
$0.94 per share; up 3% year over year
Third quarter 2026
Base Business diluted EPS
$0.97 per share; up 7% year over year
Third quarter 2026; non-GAAP
GAAP gross profit margin
60.2%; up 80 basis points year over year
Third quarter 2026
Nine-month net sales
$16,055 million; up 6% year over year
Nine months ended September 30, 2026
GAAP operating profit
$3,069 million; down 5% year over year
Nine months ended September 30, 2026
Net cash provided by operations
$2,913 million
Nine months ended September 30, 2026
Base Business EPS growth guidance
5% to 7%
Full year 2026
Key Terms
Organic sales growth, Base Business, Free cash flow before dividends
3 terms
Organic sales growth financial
"Net sales growth excluding the impact of foreign exchange, acquisitions and divestments."
Organic sales growth measures how much a company’s revenue rises from its regular business activity — like selling more products, charging higher prices, or selling to more customers — without counting money from buying other businesses or one-time currency effects. Investors watch it because it shows whether demand and the company’s core operations are genuinely getting stronger, similar to judging a garden by how much the plants you planted yourself are growing rather than by adding bought potted plants.
Base Business financial
"Base Business refers to non-GAAP measures of operating results that exclude certain items."
Free cash flow before dividends financial
"Net cash provided by operations less Capital expenditures."
Free cash flow before dividends is the cash a company keeps from its operations after covering everyday expenses and spending on long‑term items like equipment or projects, measured before any dividend payments are made. It’s like a household’s leftover money before deciding to share it with others—useful to investors because it shows whether a company has the financial room to maintain or increase payouts, invest for growth, pay down debt, or handle downturns.
Earnings Snapshot
Net sales: $5,369 million · Guidance included
Third quarter 2026
Net sales
$5,369 million
Up 4.6% year over year
GAAP diluted EPS
$0.94 per share
Up 3% year over year
Base Business diluted EPS
$0.97 per share
Up 7% year over year
GAAP gross profit margin
60.2%
Up 80 basis points year over year
Guidance
For full-year 2026, net sales growth is expected at 4% to 5%, Base Business EPS growth at 5% to 7%, and GAAP and Base Business gross profit margin to be up.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How much revenue did CL report in Q3 2026?
CL reported third-quarter net sales of $5,369 million, up 4.6% from $5,131 million a year earlier. Organic sales rose 3.6%, including a 0.2% negative impact from lower private-label pet food sales.
What is CL's updated 2026 guidance?
Based on current spot rates, net sales growth is expected at 4% to 5%, versus 2% to 6% previously, including a low-single-digit positive foreign-exchange impact. Organic sales growth is expected to be broadly in line with nine-month performance. Base Business EPS growth is expected at 5% to 7%, and GAAP and Base Business gross profit margin are expected to be up.
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
________________
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) October 30, 2026
(Exact name of registrant as specified in its charter)
(State or Other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.) | ||||||
(Address of Principal Executive Offices) | (Zip Code) | |||||||||||||
Registrant’s telephone number, including area code (212) 310-2000
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Securities registered pursuant to Securities 12(b) of the Act:
Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition.
On October 30, 2026, Colgate-Palmolive Company (the “Company”) issued a press release announcing its earnings for the quarter ended September 30, 2026. This press release is attached as Exhibit 99 and is incorporated herein by reference.
The information in Item 2.02 of this Current Report is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in Item 2.02 of this Current Report shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits. The following exhibits are filed with this document:
Exhibit Number | Description | ||||
99 | Press release, dated October 30, 2026, issued by Colgate-Palmolive Company | ||||
| 104 | Cover Page Interactive Data File (embedded within the Inline eXtensible Business Reporting Language (Inline XBRL) document) | ||||
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
>
COLGATE-PALMOLIVE COMPANY | |||||||||||
Date: October 30, 2026 | By: | /s/ Stanley J. Sutula III | |||||||||
| Name: Stanley J. Sutula III | |||||||||||
| Title: Chief Financial Officer | |||||||||||
3
Exhibit 99
Colgate-Palmolive Announces 3rd Quarter 2026 Results
•Net sales increased 4.6%; Organic sales* increased 3.6%, including a 0.2% negative impact from lower private label pet food sales
•GAAP EPS increased 3% to $0.94; Base Business EPS* increased 7% to $0.97
•GAAP Gross profit margin increased 80 basis points to 60.2%; Base Business Gross profit margin* increased 90 basis points to 60.3%
•Net cash provided by operations was $2,913 million for the first nine months of 2026
•The Company’s leadership in toothpaste continued with its global market share at 41.4% year to date
•The Company’s leadership in manual toothbrushes continued with its global market share at 33.1% year to date
•The Company narrowed its sales guidance and raised its gross profit margin and Base Business earnings per share guidance for full year 2026
Third Quarter Total Company Results (GAAP) | |||||||||||
| ($ in millions except per share amounts) | 2026 | 2025 | Change | ||||||||
| Net Sales | $5,369 | $5,131 | +4.6 | % | |||||||
| EPS (diluted) | $0.94 | $0.91 | +3 | % | |||||||
Third Quarter Total Company Results (Base Business - Non-GAAP)* | |||||||||||
| 2026 | 2025 | Change | |||||||||
| Organic Sales Growth | +3.6 | % | |||||||||
| Base Business EPS (diluted) | $0.97 | $0.91 | +7 | % | |||||||
*Indicates a non-GAAP financial measure. Please refer to “Non-GAAP Financial Measures” later in this release for definitions of non-GAAP financial measures and to “Table 6 - Geographic Sales Analysis Percentage Changes” and “Table 8 - Non-GAAP Reconciliations” included with this release for a reconciliation of these non-GAAP financial measures to the related GAAP measures.
New York, New York, October 30, 2026…Colgate-Palmolive Company (NYSE:CL) today reported results for third quarter 2026. Noel Wallace, Chairman, President and Chief Executive Officer, commented on the Base Business third quarter results, “Our growth momentum continued, delivering another strong quarter of broad-based top- and bottom-line growth with net sales and organic sales increasing in all four categories and in four of five divisions. We were particularly pleased to have delivered our fourth quarter of sequential improvement in worldwide volume growth, while delivering strong pricing growth in the third quarter. As was the case last quarter, gross profit, gross profit margin, operating profit, operating profit margin, net income, earnings per share and free cash flow all increased year over year.
“We remain focused on executing our 2030 strategy, with an emphasis on driving premium, science-based innovation, and we continue to invest behind our brands globally supported by another double-digit increase in advertising this quarter.
“Despite consumer uncertainty and ongoing macroeconomic volatility, our proactive focus on driving growth while building flexibility into our P&L gives us confidence we can navigate these challenges while continuing to deliver consistent, compounded earnings per share growth and drive long-term shareholder value.”
Full Year 2026 Guidance
Based on current spot rates:
•The Company now expects net sales to be up 4% to 5% (versus 2% to 6% previously), including a low-single-digit positive impact from foreign exchange.
•The Company now expects organic sales growth to be broadly in line with its nine-month performance (versus 1% to 4% previously). This includes the impact from our exit from the private label pet food business.
•On a GAAP basis, the Company now expects gross profit margin to be up (versus roughly flat previously) and still expects advertising to be up on both a dollar basis and as a percentage of net sales and double-digit earnings per share growth.
•On a non-GAAP (Base Business) basis, the Company now expects gross profit margin to be up (versus roughly flat previously) and still expects advertising to be up on both a dollar basis and as a percentage of net sales; it also now expects 5% to 7% earnings per share growth (versus mid-single-digit growth previously).
Divisional Performance
See attached "Table 6 - Geographic Sales Analysis Percentage Changes" and "Table 5 - Segment Information" for additional information on net sales and operating profit by division.
Third Quarter Sales Growth By Division (% change 3Q 2026 vs. 3Q 2025 except % of Total Company Sales) | ||||||||||||||||||||
| % of Total Company Sales | Net Sales | Organic Sales* | Volume | Pricing | FX | |||||||||||||||
North America(1) | 17% | -1.7% | -1.6% | -3.7% | +2.2% | -0.2% | ||||||||||||||
| Latin America | 25% | +12.5% | +6.0% | +3.9% | +2.1% | +6.5% | ||||||||||||||
Europe, Middle East & Africa(1) | 21% | +1.4% | +2.7% | +3.5% | -0.9% | -1.2% | ||||||||||||||
Asia Pacific(1) | 15% | +3.5% | +4.6% | +1.9% | +2.8% | -1.1% | ||||||||||||||
Hill’s Pet Nutrition | 22% | +5.6% | +5.7% | +1.8% | +3.9% | -0.1% | ||||||||||||||
| Total Company | 100% | +4.6% | +3.6% | +1.7% | +2.0% | +1.0% | ||||||||||||||
Table may not sum due to rounding.
(1) The Company has recast its historical geographic segment information to conform to the reporting structure effective for the quarter ended March 31, 2026. Recast historical geographic segment information can be found on the Company's website.
*Indicates a non-GAAP financial measure. Please refer to “Non-GAAP Financial Measures” later in this release for definitions of non-GAAP financial measures and to “Table 6 - Geographic Sales Analysis Percentage Changes” included with this release for a reconciliation of these non-GAAP financial measures to the related GAAP measures.
Third Quarter Operating Profit By Division ($ in millions) | ||||||||||||||
3Q 2026 | % Change vs 3Q 2025 | % to Net Sales | Change in basis points vs 3Q 2025 % to Net Sales | |||||||||||
North America(1) | $177 | -11% | 19.5% | -210 | ||||||||||
| Latin America | $392 | 17% | 29.6% | +100 | ||||||||||
Europe, Middle East & Africa(1) | $262 | 8% | 23.2% | +140 | ||||||||||
Asia Pacific(1) | $211 | -1% | 26.4% | -110 | ||||||||||
Hill’s Pet Nutrition | $267 | 5% | 22.2% | -20 | ||||||||||
| Total Company, As Reported | $1,088 | 3% | 20.3% | -30 | ||||||||||
| Total Company, Base Business* | $1,117 | 5% | 20.8% | +20 | ||||||||||
(1) The Company has recast its historical geographic segment information to conform to the reporting structure effective for the quarter ended March 31, 2026.
*Indicates a non-GAAP financial measure. Please refer to “Non-GAAP Financial Measures” later in this release for definitions of non-GAAP financial measures and to “Table 8 - Non-GAAP Reconciliations” included with this release for a reconciliation of these non-GAAP financial measures to the related GAAP measures.
Prepared Materials and Webcast Information
At approximately 7:00 a.m. ET today, the Company will post its prepared materials regarding third quarter results to the Investor Center section of its website at https://investor.colgatepalmolive.com/events-and-presentations.
At 8:30 a.m. ET today, the Company will host a conference call regarding third quarter results. To access this call as a webcast, please go to Colgate-Palmolive’s website at www.colgatepalmolive.com.
About Colgate-Palmolive
Colgate-Palmolive Company is a caring, innovative growth company that is reimagining a healthier future for all people, their pets and our planet. Focused on Oral Care, Personal Care, Home Care and Pet Nutrition, we sell our products in more than 200 countries and territories under brands such as Colgate, Palmolive, Ajax, Axion, Darlie, elmex, EltaMD, Fabuloso, Filorga, hello, Hill’s Prescription Diet, Hill’s Science Diet, Irish Spring, Lady Speed Stick, meridol, PCA SKIN, Prime100, Protex, Sanex, Softsoap, Sorriso, Soupline, Speed Stick, Suavitel and Tom’s of Maine. We are recognized for our leadership and innovation in promoting community wellbeing and improving children’s oral health through our Colgate Bright Smiles, Bright Futures program, which has reached approximately two billion children and their families since 1991. For more information about Colgate-Palmolive and how we make more smiles, visit www.colgatepalmolive.com. CL-E
Market Share Information
Management uses market share information as a key indicator to monitor business health and performance. References to market share in this press release are based on a combination of consumption and market share data provided by third-party vendors, primarily Nielsen, and internal estimates. Except as otherwise noted, all market share references represent the percentage of the dollar value of sales of our products, relative to all product sales in the category in the countries in which the Company competes and purchases data (excluding Venezuela from all periods).
Market share data is subject to limitations on the availability of up-to-date information. In particular, market share data is currently not generally available for certain retail channels, such as eCommerce and certain club retailers and discounters. The Company measures year-to-date market shares from January 1 of the relevant year through the most recent period for which market share data is available, which typically reflects a lag time of one or two months. The Company believes that the third-party vendors it uses to provide data are reliable, but it has not verified the accuracy or completeness of the data or any assumptions underlying the data. In addition, market share information reported by the Company may be different from market share information reported by other companies due to differences in category definitions, the use of data from different countries, internal estimates and other factors.
Cautionary Statement on Forward-Looking Statements
This press release and the related prepared materials and webcast may contain forward-looking statements (as that term is defined in the U.S. Private Securities Litigation Reform Act of 1995 or by the Securities and Exchange Commission (SEC) in its rules, regulations and releases) that set forth anticipated results based on management’s current plans and assumptions. Such statements may relate, for example, to sales or volume growth, net selling price increases, organic sales growth, profit or profit margin levels, earnings per share levels, financial goals, category growth rates, the impact of foreign exchange, the impact of developments in global trade relations and tariffs, the impact of geopolitical events and tensions, wars and military conflicts, such as in Ukraine and the Middle East, cost reduction plans (including the Strategic Growth and Productivity Program), tax rates, interest rates, new product introductions, digital capabilities, commercial investment levels, acquisitions, divestitures, share repurchases or legal or tax proceedings, among other matters. These statements are made on the basis of the Company’s views and assumptions as of October 30, 2026. The Company undertakes no obligation to update these statements whether as a result of new information, future events or otherwise, except as required by law or by the rules and regulations of the SEC. Moreover, the Company does not, nor does any other person, assume responsibility for the accuracy and completeness of these statements. The Company cautions investors that any such forward-looking statements are not guarantees of future performance and that actual events or results may differ materially from those statements. For more information about factors that could impact the Company’s business and cause actual results to differ materially from forward-looking statements, investors should refer to the Company’s filings with the SEC (including, but not limited to, the information set forth under the captions “Risk Factors” and “Cautionary Statement on Forward-Looking Statements” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 and subsequent filings with the SEC). Copies of these filings may be obtained upon request from the Company’s Investor Relations Department or on the Company’s website at www.colgatepalmolive.com.
Non-GAAP Financial Measures
The following provides definitions and other information regarding the non-GAAP financial measures used in this press release and the related prepared materials and webcast, which may not be the same as or comparable to similar measures presented by other companies:
•Base Business: Base Business refers to non-GAAP measures of operating results that exclude certain items. Base Business operating results exclude, as applicable, charges related to the Strategic Growth and Productivity Program and the ERISA litigation matter and acquisition-related costs.
•Organic sales growth: Net sales growth excluding the impact of foreign exchange, acquisitions and divestments.
•Free cash flow before dividends: Net cash provided by operations less Capital expenditures.
This press release and the related prepared materials and webcast discuss Net sales growth (GAAP) and Organic sales growth (non-GAAP). Management believes the organic sales growth measure provides investors and analysts with useful supplemental information regarding the Company’s underlying sales trends by presenting sales growth excluding the external factor of foreign exchange as well as the impact from acquisitions and divestments. See “Geographic Sales Analysis Percentage Changes” for the three and nine months ended September 30, 2026 versus 2025 included with this release for a comparison of Organic sales growth to Net sales growth in accordance with GAAP.
Gross profit, Gross profit margin, Selling, general and administrative expenses, Selling, general and administrative expenses as a percentage of Net sales, Other (income) expense, net, Operating profit, Operating profit margin, Non-service related postretirement costs, Effective income tax rate, Net income attributable to Colgate-Palmolive Company and Diluted earnings per common share are disclosed on both an as reported (GAAP) and Base Business (non-GAAP) basis. These non-GAAP financial measures exclude items that, either by their nature or amount, management would not expect to occur as part of the Company’s normal business on a regular basis, such as restructuring charges, charges for certain litigation and tax matters, acquisition-related costs, gains and losses from certain divestitures and certain other unusual, non-recurring items. Investors and analysts use these financial measures in assessing the Company’s business performance, and management believes that presenting these financial measures on a non-GAAP basis provides them with useful supplemental information to enhance their understanding of the Company’s underlying business performance and trends. These non-GAAP financial measures also enhance the ability to compare period-to-period financial results. See “Non-GAAP Reconciliations” for the three and nine months ended September 30, 2026 and 2025 included with this release for a reconciliation of these financial measures to the related GAAP measures.
The Company uses these financial measures internally in its budgeting process, to evaluate segment and overall operating performance and as factors in determining compensation. While the Company believes that these financial measures are useful in evaluating the Company’s underlying business performance and trends, this information should be considered as supplemental in nature and is not meant to be considered in isolation or as a substitute for the related financial information prepared in accordance with GAAP.
As management uses free cash flow before dividends to evaluate the Company’s ability to satisfy current and future obligations, pay dividends, fund future business opportunities and repurchase stock, the Company believes that it provides useful information to investors. Free cash flow before dividends is not a measure of cash available for discretionary expenditures since the Company has certain non-discretionary obligations such as debt service that are not deducted from the measure. See “Condensed Consolidated Statements of Cash Flows” for the nine months ended September 30, 2026 and 2025 for a comparison of free cash flow before dividends to Net cash provided by operations as reported in accordance with GAAP.
(See attached tables for third quarter results.)
Contacts
Investor Relations: investor_relations@colpal.com
Communications: colgate_palmolive_media_inquiry@colpal.com
| Table 1 | ||||||||||||||
| Colgate-Palmolive Company | ||||||||||||||
| Condensed Consolidated Statements of Income | ||||||||||||||
| For the Three Months Ended September 30, 2026 and 2025 | ||||||||||||||
| (Dollars in Millions Except Per Share Amounts) (Unaudited) | ||||||||||||||
| 2026 | 2025 | |||||||||||||
| Net sales | $ | 5,369 | $ | 5,131 | ||||||||||
| Cost of sales | 2,136 | 2,082 | ||||||||||||
| Gross profit | 3,233 | 3,049 | ||||||||||||
| Gross profit margin | 60.2 | % | 59.4 | % | ||||||||||
| Selling, general and administrative expenses | 2,111 | 1,971 | ||||||||||||
| Other (income) expense, net | 34 | 19 | ||||||||||||
| Operating profit | 1,088 | 1,059 | ||||||||||||
| Operating profit margin | 20.3 | % | 20.6 | % | ||||||||||
| Non-service related postretirement costs | 24 | 21 | ||||||||||||
| Interest expense | 62 | 67 | ||||||||||||
| Interest income | 17 | 21 | ||||||||||||
| Income before income taxes | 1,019 | 992 | ||||||||||||
| Provision for income taxes | 240 | 226 | ||||||||||||
| Effective tax rate | 23.6 | % | 22.8 | % | ||||||||||
| Net income including noncontrolling interests | 779 | 766 | ||||||||||||
| Less: Net income attributable to noncontrolling interests | 28 | 31 | ||||||||||||
| Net income attributable to Colgate-Palmolive Company | $ | 751 | $ | 735 | ||||||||||
| Earnings per common share | ||||||||||||||
| Basic | $ | 0.94 | $ | 0.91 | ||||||||||
| Diluted | $ | 0.94 | $ | 0.91 | ||||||||||
| Supplemental Income Statement Information | ||||||||||||||
| Average common shares outstanding | ||||||||||||||
| Basic | 796.9 | 807.8 | ||||||||||||
| Diluted | 799.7 | 810.2 | ||||||||||||
| Advertising | $ | 775 | $ | 674 | ||||||||||
| Table 2 | ||||||||||||||
| Colgate-Palmolive Company | ||||||||||||||
| Condensed Consolidated Statements of Income | ||||||||||||||
| For the Nine Months Ended September 30, 2026 and 2025 | ||||||||||||||
| (Dollars in Millions Except Per Share Amounts) (Unaudited) | ||||||||||||||
| 2026 | 2025 | |||||||||||||
| Net sales | $ | 16,055 | $ | 15,152 | ||||||||||
| Cost of sales | 6,300 | 6,047 | ||||||||||||
| Gross profit | 9,755 | 9,105 | ||||||||||||
| Gross profit margin | 60.8 | % | 60.1 | % | ||||||||||
| Selling, general and administrative expenses | 6,316 | 5,833 | ||||||||||||
| Other (income) expense, net | 370 | 58 | ||||||||||||
| Operating profit | 3,069 | 3,214 | ||||||||||||
| Operating profit margin | 19.1 | % | 21.2 | % | ||||||||||
| Non-service related postretirement costs | 70 | 116 | ||||||||||||
| Interest expense | 186 | 203 | ||||||||||||
| Interest income | 50 | 56 | ||||||||||||
| Income before income taxes | 2,863 | 2,951 | ||||||||||||
| Provision for income taxes | 682 | 685 | ||||||||||||
| Effective tax rate | 23.8 | % | 23.2 | % | ||||||||||
| Net income including noncontrolling interests | 2,181 | 2,266 | ||||||||||||
| Less: Net income attributable to noncontrolling interests | 91 | 97 | ||||||||||||
| Net income attributable to Colgate-Palmolive Company | $ | 2,090 | $ | 2,169 | ||||||||||
| Earnings per common share | ||||||||||||||
Basic(1) | $ | 2.61 | $ | 2.68 | ||||||||||
Diluted(1) | $ | 2.61 | $ | 2.67 | ||||||||||
| Supplemental Income Statement Information | ||||||||||||||
| Average common shares outstanding | ||||||||||||||
| Basic | 799.5 | 810.0 | ||||||||||||
| Diluted | 802.2 | 812.8 | ||||||||||||
| Advertising | $ | 2,286 | $ | 2,020 | ||||||||||
| Note: (1) Basic and diluted earnings per share are computed independently for each quarter and any year-to-date period presented. As a result of changes in shares outstanding during the year and rounding, the sum of the quarters' earnings per share may not equal the earnings per share for any year-to-date period. | ||||||||||||||
| Table 3 | ||||||||||||||||||||
| Colgate-Palmolive Company | ||||||||||||||||||||
| Condensed Consolidated Balance Sheets | ||||||||||||||||||||
| As of September 30, 2026, December 31, 2025 and September 30, 2025 | ||||||||||||||||||||
| (Dollars in Millions) (Unaudited) | ||||||||||||||||||||
| September 30, | December 31, | September 30, | ||||||||||||||||||
| 2026 | 2025 | 2025 | ||||||||||||||||||
| Cash and cash equivalents | $ | 1,527 | $ | 1,288 | $ | 1,279 | ||||||||||||||
| Receivables, net | 1,901 | 1,675 | 1,807 | |||||||||||||||||
| Inventories | 2,182 | 2,032 | 2,109 | |||||||||||||||||
| Other current assets | 747 | 714 | 844 | |||||||||||||||||
| Property, plant and equipment, net | 4,613 | 4,660 | 4,560 | |||||||||||||||||
| Goodwill | 3,080 | 3,122 | 3,702 | |||||||||||||||||
| Other intangible assets, net | 1,472 | 1,536 | 1,889 | |||||||||||||||||
| Other assets | 1,220 | 1,303 | 1,323 | |||||||||||||||||
| Total assets | $ | 16,742 | $ | 16,330 | $ | 17,513 | ||||||||||||||
| Total debt | $ | 7,716 | $ | 7,988 | $ | 8,419 | ||||||||||||||
| Other current liabilities | 6,107 | 5,736 | 5,383 | |||||||||||||||||
| Other non-current liabilities | 2,279 | 2,241 | 2,473 | |||||||||||||||||
| Total liabilities | 16,102 | 15,965 | 16,275 | |||||||||||||||||
| Total Colgate-Palmolive Company shareholders’ equity | 288 | 54 | 856 | |||||||||||||||||
| Noncontrolling interests | 352 | 311 | 382 | |||||||||||||||||
| Total liabilities and equity | $ | 16,742 | $ | 16,330 | $ | 17,513 | ||||||||||||||
| Supplemental Balance Sheet Information | ||||||||||||||||||||
Debt less cash, cash equivalents and marketable securities(1) | $ | 6,104 | $ | 6,593 | $ | 6,947 | ||||||||||||||
| Working capital % of sales | (6.3) | % | (7.0) | % | (4.0) | % | ||||||||||||||
Note:
(1) Marketable securities of $85, $107 and $193 as of September 30, 2026, December 31, 2025 and September 30, 2025, respectively, are included in Other current assets.
| Table 4 | ||||||||||||||
| Colgate-Palmolive Company | ||||||||||||||
| Condensed Consolidated Statements of Cash Flows | ||||||||||||||
| For the Nine Months Ended September 30, 2026 and 2025 | ||||||||||||||
| (Dollars in Millions) (Unaudited) | ||||||||||||||
| 2026 | 2025 | |||||||||||||
| Operating Activities | ||||||||||||||
| Net income including noncontrolling interests | $ | 2,181 | $ | 2,266 | ||||||||||
| Adjustments to reconcile net income including noncontrolling interests to net cash provided by operations: | ||||||||||||||
| Depreciation and amortization | 470 | 457 | ||||||||||||
| ERISA litigation matter | — | 65 | ||||||||||||
| Restructuring and termination benefits, net of cash | 177 | (15) | ||||||||||||
| Stock-based compensation expense | 141 | 127 | ||||||||||||
| Deferred income taxes | 54 | 8 | ||||||||||||
| Cash effects of changes in: | ||||||||||||||
| Receivables | (224) | (180) | ||||||||||||
| Inventories | (104) | 9 | ||||||||||||
| Accounts payable and other working capital | 254 | 30 | ||||||||||||
| Other non-current assets | 48 | 48 | ||||||||||||
| Other non-current liabilities | (84) | (70) | ||||||||||||
| Net cash provided by (used in) operations | 2,913 | 2,745 | ||||||||||||
| Investing Activities | ||||||||||||||
| Capital expenditures | (400) | (387) | ||||||||||||
| Purchases of marketable securities and investments | (163) | (537) | ||||||||||||
| Proceeds from sale of marketable securities and investments | 187 | 508 | ||||||||||||
| Payment for acquisition, net of cash acquired | — | (293) | ||||||||||||
| Other investing activities | (5) | (5) | ||||||||||||
| Net cash provided by (used in) investing activities | (381) | (714) | ||||||||||||
| Financing Activities | ||||||||||||||
| Short-term borrowing (repayment) less than 90 days, net | 947 | 139 | ||||||||||||
| Principal payments on debt | (1,087) | (655) | ||||||||||||
| Proceeds from issuance of debt | — | 497 | ||||||||||||
| Dividends paid | (1,308) | (1,300) | ||||||||||||
| Purchases of treasury shares | (927) | (804) | ||||||||||||
| Proceeds from exercise of stock options | 178 | 83 | ||||||||||||
| Other financing activities | (75) | 145 | ||||||||||||
| Net cash provided by (used in) financing activities | (2,272) | (1,895) | ||||||||||||
| Effect of exchange rate changes on Cash and cash equivalents | (21) | 47 | ||||||||||||
| Net increase (decrease) in Cash and cash equivalents | 239 | 183 | ||||||||||||
| Cash and cash equivalents at beginning of the period | 1,288 | 1,096 | ||||||||||||
| Cash and cash equivalents at end of the period | $ | 1,527 | $ | 1,279 | ||||||||||
| Supplemental Cash Flow Information | ||||||||||||||
| Free cash flow before dividends (Net cash provided by operations less Capital expenditures) | ||||||||||||||
| Net cash provided by operations | $ | 2,913 | $ | 2,745 | ||||||||||
| Less: Capital expenditures | (400) | (387) | ||||||||||||
| Free cash flow before dividends | $ | 2,513 | $ | 2,358 | ||||||||||
| Income taxes paid | $ | 648 | $ | 712 | ||||||||||
| Interest paid | $ | 205 | $ | 235 | ||||||||||
| Table 5 | ||||||||||||||||||||||||||
| Colgate-Palmolive Company | ||||||||||||||||||||||||||
| Segment Information | ||||||||||||||||||||||||||
| For the Three and Nine Months Ended September 30, 2026 and 2025 | ||||||||||||||||||||||||||
| (Dollars in Millions) (Unaudited) | ||||||||||||||||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||||||||||||
| Net Sales | ||||||||||||||||||||||||||
| Oral, Personal and Home Care | ||||||||||||||||||||||||||
North America(1) | $ | 905 | $ | 922 | $ | 2,684 | $ | 2,745 | ||||||||||||||||||
| Latin America | 1,326 | 1,178 | 4,011 | 3,528 | ||||||||||||||||||||||
Europe, Middle East & Africa(1) | 1,130 | 1,115 | 3,377 | 3,204 | ||||||||||||||||||||||
Asia Pacific(1) | 802 | 775 | 2,388 | 2,259 | ||||||||||||||||||||||
| Total Oral, Personal and Home Care | 4,164 | 3,989 | 12,461 | 11,735 | ||||||||||||||||||||||
| Hill's Pet Nutrition | 1,205 | 1,142 | 3,594 | 3,417 | ||||||||||||||||||||||
| Total Net Sales | $ | 5,369 | $ | 5,131 | $ | 16,055 | $ | 15,152 | ||||||||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||||||||||||
| Operating Profit | ||||||||||||||||||||||||||
| Oral, Personal and Home Care | ||||||||||||||||||||||||||
North America(1) | $ | 177 | $ | 199 | $ | 510 | $ | 583 | ||||||||||||||||||
| Latin America | 392 | 337 | 1,211 | 1,052 | ||||||||||||||||||||||
Europe, Middle East & Africa(1) | 262 | 243 | 791 | 706 | ||||||||||||||||||||||
Asia Pacific(1) | 211 | 213 | 643 | 620 | ||||||||||||||||||||||
| Total Oral, Personal and Home Care | 1,042 | 992 | 3,155 | 2,961 | ||||||||||||||||||||||
| Hill's Pet Nutrition | 267 | 255 | 816 | 778 | ||||||||||||||||||||||
Corporate(2) | (221) | (189) | (902) | (523) | ||||||||||||||||||||||
| Total Operating Profit | $ | 1,088 | $ | 1,059 | $ | 3,069 | $ | 3,214 | ||||||||||||||||||
Tables may not sum due to rounding.
Notes:
(1) The Company has recast its historical geographic segment information to conform to the reporting structure effective for the quarter ended March 31, 2026.
(2) Corporate operations include costs related to stock options and restricted stock units, research and development costs, Corporate overhead costs, restructuring and related implementation charges and gains and losses on sales of non-core product lines and assets.
Corporate Operating profit (loss) for the three and nine months ended September 30, 2026 included charges resulting from the Strategic Growth and Productivity Program of $29 and $327, respectively.
Corporate Operating profit (loss) for the nine months ended September 30, 2025 included charges resulting from the ERISA litigation matter of $15 and acquisition-related costs of $9.
| Table 6 | ||||||||||||||||||||||||||||||||
| Colgate-Palmolive Company | ||||||||||||||||||||||||||||||||
| Geographic Sales Analysis Percentage Changes | ||||||||||||||||||||||||||||||||
| For the Three Months Ended September 30, 2026 vs. 2025 | ||||||||||||||||||||||||||||||||
| (Unaudited) | ||||||||||||||||||||||||||||||||
| COMPONENTS OF SALES CHANGE | ||||||||||||||||||||||||||||||||
| Pricing | ||||||||||||||||||||||||||||||||
| Coupons | ||||||||||||||||||||||||||||||||
| Sales | Consumer & | |||||||||||||||||||||||||||||||
| Change | Organic | Trade | Foreign | |||||||||||||||||||||||||||||
| Region | As Reported | Sales Change | Volume | Incentives | Exchange | |||||||||||||||||||||||||||
| Total Company | 4.6 | % | 3.6 | % | 1.7 | % | 2.0 | % | 1.0 | % | ||||||||||||||||||||||
North America(1) | (1.7) | % | (1.6) | % | (3.7) | % | 2.2 | % | (0.2) | % | ||||||||||||||||||||||
| Latin America | 12.5 | % | 6.0 | % | 3.9 | % | 2.1 | % | 6.5 | % | ||||||||||||||||||||||
Europe, Middle East & Africa(1) | 1.4 | % | 2.7 | % | 3.5 | % | (0.9) | % | (1.2) | % | ||||||||||||||||||||||
Asia Pacific(1) | 3.5 | % | 4.6 | % | 1.9 | % | 2.8 | % | (1.1) | % | ||||||||||||||||||||||
| Total CP Products | 4.4 | % | 3.1 | % | 1.6 | % | 1.4 | % | 1.3 | % | ||||||||||||||||||||||
| Hill’s Pet Nutrition | 5.6 | % | 5.7 | % | 1.8 | % | 3.9 | % | (0.1) | % | ||||||||||||||||||||||
Emerging Markets(2) | 8.0 | % | 5.4 | % | 3.7 | % | 1.7 | % | 2.7 | % | ||||||||||||||||||||||
Developed Markets | 2.0 | % | 2.3 | % | 0.1 | % | 2.2 | % | (0.3) | % | ||||||||||||||||||||||
Table may not sum due to rounding.
Notes:
(1) The Company has recast its historical geographic segment information to conform to the reporting structure effective for the quarter ended March 31, 2026.
(2) Emerging Markets include Latin America, Asia (excluding Japan), Africa, the Middle East and Eastern and Central Europe.
| Table 7 | ||||||||||||||||||||||||||||||||||||||
| Colgate-Palmolive Company | ||||||||||||||||||||||||||||||||||||||
| Geographic Sales Analysis Percentage Changes | ||||||||||||||||||||||||||||||||||||||
| For the Nine Months Ended September 30, 2026 vs. 2025 | ||||||||||||||||||||||||||||||||||||||
| (Unaudited) | ||||||||||||||||||||||||||||||||||||||
| COMPONENTS OF SALES CHANGE | ||||||||||||||||||||||||||||||||||||||
| Pricing | ||||||||||||||||||||||||||||||||||||||
| Coupons | ||||||||||||||||||||||||||||||||||||||
| Sales | Consumer & | |||||||||||||||||||||||||||||||||||||
| Change | Organic | As Reported | Organic | Trade | Foreign | |||||||||||||||||||||||||||||||||
| Region | As Reported | Sales Change | Volume(1) | Volume | Incentives | Exchange | ||||||||||||||||||||||||||||||||
| Total Company | 6.0 | % | 3.0 | % | 1.2 | % | 1.0 | % | 1.9 | % | 2.8 | % | ||||||||||||||||||||||||||
North America(2) | (2.2) | % | (2.3) | % | (3.6) | % | (3.6) | % | 1.4 | % | 0.1 | % | ||||||||||||||||||||||||||
| Latin America | 13.7 | % | 5.6 | % | 2.8 | % | 2.8 | % | 2.7 | % | 8.1 | % | ||||||||||||||||||||||||||
Europe, Middle East & Africa(2) | 5.4 | % | 2.7 | % | 3.0 | % | 3.0 | % | (0.3) | % | 2.8 | % | ||||||||||||||||||||||||||
Asia Pacific(2) | 5.7 | % | 5.1 | % | 3.5 | % | 3.5 | % | 1.6 | % | 0.6 | % | ||||||||||||||||||||||||||
| Total CP Products | 6.2 | % | 2.9 | % | 1.5 | % | 1.5 | % | 1.4 | % | 3.3 | % | ||||||||||||||||||||||||||
| Hill’s Pet Nutrition | 5.2 | % | 3.3 | % | 0.3 | % | (0.6) | % | 3.9 | % | 1.1 | % | ||||||||||||||||||||||||||
Emerging Markets(3) | 10.0 | % | 5.4 | % | 3.3 | % | 3.3 | % | 2.1 | % | 4.6 | % | ||||||||||||||||||||||||||
| Developed Markets | 2.8 | % | 1.0 | % | (0.5) | % | (0.8) | % | 1.8 | % | 1.4 | % | ||||||||||||||||||||||||||
Table may not sum due to rounding.
Notes:
(1) The impact of the acquisition of the Prime100 pet food business on as reported volume was 0.2%, 0.8% and 0.3% for Total Company, Hill's Pet Nutrition and Developed Markets, respectively.
(2) The Company has recast its historical geographic segment information to conform to the reporting structure effective for the quarter ended March 31, 2026.
(3) Emerging Markets include Latin America, Asia (excluding Japan), Africa, the Middle East and Eastern and Central Europe.
| Table 8 | |||||||||||||||||||||||||||||||||||||||||||||||
| Colgate-Palmolive Company | |||||||||||||||||||||||||||||||||||||||||||||||
| Non-GAAP Reconciliations | |||||||||||||||||||||||||||||||||||||||||||||||
| For the Three Months Ended September 30, 2026 and 2025 | |||||||||||||||||||||||||||||||||||||||||||||||
| (Dollars in Millions Except Per Share Amounts) (Unaudited) | |||||||||||||||||||||||||||||||||||||||||||||||
| Gross Profit | 2026 | 2025 | |||||||||||||||||||||||||||||||||||||||||||||
| Gross profit, GAAP | $ | 3,233 | $ | 3,049 | |||||||||||||||||||||||||||||||||||||||||||
| Strategic Growth and Productivity Program | 5 | — | |||||||||||||||||||||||||||||||||||||||||||||
| Gross profit, non-GAAP | $ | 3,238 | $ | 3,049 | |||||||||||||||||||||||||||||||||||||||||||
| Basis Point | |||||||||||||||||||||||||||||||||||||||||||||||
| Gross Profit Margin | 2026 | 2025 | Change | ||||||||||||||||||||||||||||||||||||||||||||
| Gross profit margin, GAAP | 60.2 | % | 59.4 | % | 80 | ||||||||||||||||||||||||||||||||||||||||||
| Strategic Growth and Productivity Program | 0.1 | % | — | % | |||||||||||||||||||||||||||||||||||||||||||
| Gross profit margin, non-GAAP | 60.3 | % | 59.4 | % | 90 | ||||||||||||||||||||||||||||||||||||||||||
| Selling, General and Administrative Expenses | 2026 | 2025 | |||||||||||||||||||||||||||||||||||||||||||||
| Selling, general and administrative expenses, GAAP | $ | 2,111 | $ | 1,971 | |||||||||||||||||||||||||||||||||||||||||||
| Strategic Growth and Productivity Program | (9) | — | |||||||||||||||||||||||||||||||||||||||||||||
| Selling, general and administrative expenses, non-GAAP | $ | 2,102 | $ | 1,971 | |||||||||||||||||||||||||||||||||||||||||||
| Basis Point | |||||||||||||||||||||||||||||||||||||||||||||||
| Selling, General and Administrative Expenses as a Percentage of Net Sales | 2026 | 2025 | Change | ||||||||||||||||||||||||||||||||||||||||||||
| Selling, general and administrative expenses as a percentage of Net sales, GAAP | 39.3 | % | 38.4 | % | 90 | ||||||||||||||||||||||||||||||||||||||||||
| Strategic Growth and Productivity Program | (0.2) | % | — | % | |||||||||||||||||||||||||||||||||||||||||||
| Selling, general and administrative expenses as a percentage of Net sales, non-GAAP | 39.1 | % | 38.4 | % | 70 | ||||||||||||||||||||||||||||||||||||||||||
| Other (Income) Expense, Net | 2026 | 2025 | |||||||||||||||||||||||||||||||||||||||||||||
| Other (income) expense, net, GAAP | $ | 34 | $ | 19 | |||||||||||||||||||||||||||||||||||||||||||
| Strategic Growth and Productivity Program | (15) | — | |||||||||||||||||||||||||||||||||||||||||||||
| Other (income) expense, net, non-GAAP | $ | 19 | $ | 19 | |||||||||||||||||||||||||||||||||||||||||||
| Operating Profit | 2026 | 2025 | % Change | ||||||||||||||||||||||||||||||||||||||||||||
| Operating profit, GAAP | $ | 1,088 | $ | 1,059 | 3 | % | |||||||||||||||||||||||||||||||||||||||||
| Strategic Growth and Productivity Program | 29 | — | |||||||||||||||||||||||||||||||||||||||||||||
| Operating profit, non-GAAP | $ | 1,117 | $ | 1,059 | 5 | % | |||||||||||||||||||||||||||||||||||||||||
| Basis Point | |||||||||||||||||||||||||||||||||||||||||||||||
| Operating Profit Margin | 2026 | 2025 | Change | ||||||||||||||||||||||||||||||||||||||||||||
| Operating profit margin, GAAP | 20.3 | % | 20.6 | % | (30) | ||||||||||||||||||||||||||||||||||||||||||
| Strategic Growth and Productivity Program | 0.5 | % | — | % | |||||||||||||||||||||||||||||||||||||||||||
| Operating profit margin, non-GAAP | 20.8 | % | 20.6 | % | 20 | ||||||||||||||||||||||||||||||||||||||||||
| Non-Service Related Postretirement Costs | 2026 | 2025 | |||||||||||||||||||||||||||||||||||||||||||||
| Non-service related postretirement costs, GAAP | $ | 24 | $ | 21 | |||||||||||||||||||||||||||||||||||||||||||
| Strategic Growth and Productivity Program | (1) | — | |||||||||||||||||||||||||||||||||||||||||||||
| Non-service related postretirement costs, non-GAAP | $ | 23 | $ | 21 | |||||||||||||||||||||||||||||||||||||||||||
Note: The impact of non-GAAP adjustments may not necessarily equal the difference between “GAAP” and “non-GAAP” as a result of rounding. | |||||||||||||||||||||||||||||||||||||||||||||||
| Table 8 | |||||||||||||||||||||||||||||||||||||||||||||||
| Continued | |||||||||||||||||||||||||||||||||||||||||||||||
| Colgate-Palmolive Company | |||||||||||||||||||||||||||||||||||||||||||||||
| Non-GAAP Reconciliations | |||||||||||||||||||||||||||||||||||||||||||||||
| For the Three Months Ended September 30, 2026 | |||||||||||||||||||||||||||||||||||||||||||||||
| (Dollars in Millions Except Per Share Amounts) (Unaudited) | |||||||||||||||||||||||||||||||||||||||||||||||
| 2026 | |||||||||||||||||||||||||||||||||||||||||||||||
| Income Before Income Taxes | Provision For Income Taxes(1) | Net Income Including Noncontrolling Interests | Less: Income Attributable to Noncontrolling Interests | Net Income Attributable To Colgate-Palmolive Company | Effective Income Tax Rate(2) | Diluted Earnings Per Share | |||||||||||||||||||||||||||||||||||||||||
| As Reported GAAP | $ | 1,019 | $ | 240 | $ | 779 | $ | 28 | $ | 751 | 23.6 | % | $ | 0.94 | |||||||||||||||||||||||||||||||||
| Strategic Growth and Productivity Program | 30 | 3 | 26 | — | 26 | (0.3) | % | 0.03 | |||||||||||||||||||||||||||||||||||||||
| Non-GAAP | $ | 1,049 | $ | 244 | $ | 805 | $ | 28 | $ | 777 | 23.3 | % | $ | 0.97 | |||||||||||||||||||||||||||||||||
The impact of non-GAAP adjustments may not necessarily equal the difference between “GAAP” and “non-GAAP” as a result of rounding.
Notes:
(1) The income tax effect on non-GAAP items is calculated based upon the tax laws and statutory income tax rates applicable in the tax jurisdiction(s) of the underlying non-GAAP adjustment.
(2) The impact of non-GAAP items on the Company’s effective tax rate represents the difference in the effective tax rate calculated with and without the non-GAAP adjustment on Income before income taxes and Provision for income taxes.
| Table 9 | |||||||||||||||||||||||||||||||||||||||||||||||
| Colgate-Palmolive Company | |||||||||||||||||||||||||||||||||||||||||||||||
| Non-GAAP Reconciliations | |||||||||||||||||||||||||||||||||||||||||||||||
| For the Nine Months Ended September 30, 2026 and 2025 | |||||||||||||||||||||||||||||||||||||||||||||||
| (Dollars in Millions Except Per Share Amounts) (Unaudited) | |||||||||||||||||||||||||||||||||||||||||||||||
| Gross Profit | 2026 | 2025 | |||||||||||||||||||||||||||||||||||||||||||||
| Gross profit, GAAP | $ | 9,755 | $ | 9,105 | |||||||||||||||||||||||||||||||||||||||||||
| Strategic Growth and Productivity Program | 7 | — | |||||||||||||||||||||||||||||||||||||||||||||
| Gross profit, non-GAAP | $ | 9,762 | $ | 9,105 | |||||||||||||||||||||||||||||||||||||||||||
| Selling, General and Administrative Expenses | 2026 | 2025 | |||||||||||||||||||||||||||||||||||||||||||||
| Selling, general and administrative expenses, GAAP | $ | 6,316 | $ | 5,833 | |||||||||||||||||||||||||||||||||||||||||||
| Strategic Growth and Productivity Program | (20) | — | |||||||||||||||||||||||||||||||||||||||||||||
| ERISA litigation matter | — | (15) | |||||||||||||||||||||||||||||||||||||||||||||
| Selling, general and administrative expenses, non-GAAP | $ | 6,296 | $ | 5,817 | |||||||||||||||||||||||||||||||||||||||||||
| Basis Point | |||||||||||||||||||||||||||||||||||||||||||||||
| Selling, General and Administrative Expenses as a Percentage of Net Sales | 2026 | 2025 | Change | ||||||||||||||||||||||||||||||||||||||||||||
| Selling, general and administrative expenses as a percentage of Net sales, GAAP | 39.3 | % | 38.5 | % | 80 | ||||||||||||||||||||||||||||||||||||||||||
| Strategic Growth and Productivity Program | (0.1) | % | — | % | |||||||||||||||||||||||||||||||||||||||||||
| ERISA litigation matter | — | % | (0.1) | % | |||||||||||||||||||||||||||||||||||||||||||
| Selling, general and administrative expenses as a percentage of Net sales, non-GAAP | 39.2 | % | 38.4 | % | 80 | ||||||||||||||||||||||||||||||||||||||||||
| Other (Income) Expense, Net | 2026 | 2025 | |||||||||||||||||||||||||||||||||||||||||||||
| Other (income) expense, net, GAAP | $ | 370 | $ | 58 | |||||||||||||||||||||||||||||||||||||||||||
| Strategic Growth and Productivity Program | (300) | — | |||||||||||||||||||||||||||||||||||||||||||||
| Acquisition-related costs | — | (9) | |||||||||||||||||||||||||||||||||||||||||||||
| Other (income) expense, net, non-GAAP | $ | 70 | $ | 48 | |||||||||||||||||||||||||||||||||||||||||||
| Operating Profit | 2026 | 2025 | % Change | ||||||||||||||||||||||||||||||||||||||||||||
Operating profit, GAAP | $ | 3,069 | $ | 3,214 | (5) | % | |||||||||||||||||||||||||||||||||||||||||
| Strategic Growth and Productivity Program | 327 | — | |||||||||||||||||||||||||||||||||||||||||||||
| ERISA litigation matter | — | 15 | |||||||||||||||||||||||||||||||||||||||||||||
| Acquisition-related costs | — | 9 | |||||||||||||||||||||||||||||||||||||||||||||
Operating profit, non-GAAP | $ | 3,396 | $ | 3,240 | 5 | % | |||||||||||||||||||||||||||||||||||||||||
| Basis Point | |||||||||||||||||||||||||||||||||||||||||||||||
| Operating Profit Margin | 2026 | 2025 | Change | ||||||||||||||||||||||||||||||||||||||||||||
| Operating profit margin, GAAP | 19.1 | % | 21.2 | % | (210) | ||||||||||||||||||||||||||||||||||||||||||
| Strategic Growth and Productivity Program | 2.1 | % | — | % | |||||||||||||||||||||||||||||||||||||||||||
| ERISA litigation matter | — | % | 0.1 | % | |||||||||||||||||||||||||||||||||||||||||||
| Acquisition-related costs | — | % | 0.1 | % | |||||||||||||||||||||||||||||||||||||||||||
| Operating profit margin, non-GAAP | 21.2 | % | 21.4 | % | (20) | ||||||||||||||||||||||||||||||||||||||||||
| Non-Service Related Postretirement Costs | 2026 | 2025 | |||||||||||||||||||||||||||||||||||||||||||||
| Non-service related postretirement costs, GAAP | $ | 70 | $ | 116 | |||||||||||||||||||||||||||||||||||||||||||
| Strategic Growth and Productivity Program | (6) | — | |||||||||||||||||||||||||||||||||||||||||||||
| ERISA litigation matter | — | (50) | |||||||||||||||||||||||||||||||||||||||||||||
| Non-service related postretirement costs, non-GAAP | $ | 64 | $ | 66 | |||||||||||||||||||||||||||||||||||||||||||
Note: The impact of non-GAAP adjustments may not necessarily equal the difference between “GAAP” and “non-GAAP” as a result of rounding. | |||||||||||||||||||||||||||||||||||||||||||||||
| Table 9 | |||||||||||||||||||||||||||||||||||||||||||||||
| Continued | |||||||||||||||||||||||||||||||||||||||||||||||
| Colgate-Palmolive Company | |||||||||||||||||||||||||||||||||||||||||||||||
| Non-GAAP Reconciliations | |||||||||||||||||||||||||||||||||||||||||||||||
| For the Nine Months Ended September 30, 2026 and 2025 | |||||||||||||||||||||||||||||||||||||||||||||||
| (Dollars in Millions Except Per Share Amounts) (Unaudited) | |||||||||||||||||||||||||||||||||||||||||||||||
| 2026 | |||||||||||||||||||||||||||||||||||||||||||||||
| Income Before Income Taxes | Provision For Income Taxes(1) | Net Income Including Noncontrolling Interests | Less: Income Attributable to Noncontrolling Interests | Net Income Attributable To Colgate-Palmolive Company | Effective Income Tax Rate(2) | Diluted Earnings Per Share | |||||||||||||||||||||||||||||||||||||||||
| As Reported GAAP | $ | 2,863 | $ | 682 | $ | 2,181 | $ | 91 | $ | 2,090 | 23.8 | % | $ | 2.61 | |||||||||||||||||||||||||||||||||
| Strategic Growth and Productivity Program | 333 | 64 | 269 | 1 | 268 | (0.5) | % | 0.33 | |||||||||||||||||||||||||||||||||||||||
| Non-GAAP | $ | 3,196 | $ | 746 | $ | 2,450 | $ | 91 | $ | 2,359 | 23.3 | % | $ | 2.94 | |||||||||||||||||||||||||||||||||
| 2025 | |||||||||||||||||||||||||||||||||||||||||||||||
| Income Before Income Taxes | Provision For Income Taxes(1) | Net Income Including Noncontrolling Interests | Less: Income Attributable to Noncontrolling Interests | Net Income Attributable To Colgate-Palmolive Company | Effective Income Tax Rate(2) | Diluted Earnings Per Share | |||||||||||||||||||||||||||||||||||||||||
| As Reported GAAP | $ | 2,951 | $ | 685 | $ | 2,266 | $ | 97 | $ | 2,169 | 23.2 | % | $ | 2.67 | |||||||||||||||||||||||||||||||||
| ERISA litigation matter | 65 | 12 | 53 | — | 53 | — | % | 0.06 | |||||||||||||||||||||||||||||||||||||||
| Acquisition-related costs | 9 | 2 | 7 | — | 7 | — | % | 0.01 | |||||||||||||||||||||||||||||||||||||||
| Non-GAAP | $ | 3,027 | $ | 702 | $ | 2,325 | $ | 97 | $ | 2,228 | 23.2 | % | $ | 2.74 | |||||||||||||||||||||||||||||||||
The impact of non-GAAP adjustments may not necessarily equal the difference between “GAAP” and “non-GAAP” as a result of rounding.
Notes:
(1) The income tax effect on non-GAAP items is calculated based upon the tax laws and statutory income tax rates applicable in the tax jurisdiction(s) of the underlying non-GAAP adjustment.
(2) The impact of non-GAAP items on the Company’s effective tax rate represents the difference in the effective tax rate calculated with and without the non-GAAP adjustment on Income before income taxes and Provision for income taxes.